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Background: Flow response after administration of a bronchodilator is widely used as an
indicator of reversibility of airflow limitation in chronic obstructive pulmonary disease
(COPD). We hypothesized that the association between flow and volume responses would
reverse along with the progression of the disease.
Methods: We used the database of a large primary care diagnostic centre containing pre-
and postbronchodilator tests of patients referred for spirometry by their GP. PatientsX40
years with a smoking history were categorized into Global initiative for chronic obstructive
lung disease (GOLD) stages I–IV. Flow and volume responses (DFVC and DFEV1,
respectively) were calculated and compared between the GOLD stages using linear
regression analysis.
Results: About 2210 patients (63% males, 49% current smokers) were analysed. Four
hundred and forty-two patients were classified into GOLD stage I, 1297 in GOLD II, 426 in
GOLD III, and 45 in GOLD IV. The overall mean values for DFEV1 and DFVC were 0.180 (SD
0.150) and 0.226 l (SD 0.227). DFEV1 decreased as the GOLD stage was more severe,
whereas DFVC increased (Po0.001). There was a clear positive correlation between DFEV1
and DFVC within each GOLD stage (Po0.01), but when FVC response was plotted against
FEV1 response the slope of the regression line became gradually steeper with each more
severe GOLD stage (Po0.001).
Conclusions: Our hypothesis that COPD patients on the mild side of the severity spectrum
differ from patients on the severe side regarding the association between their
bronchodilator flow and volume responses was confirmed. The difference is probablyElsevier Ltd. All rights reserved.
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T. Schermer et al.1356explained by the higher degree of loss of lung elastic recoil and/or compression of the
smaller airways due to enlarged air spaces that accompanies the progression of COPD to
the more severe stages.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is defined as
a disease state that is characterized by a progressive and not
fully reversible airflow limitation.1 The Global Initiative for
chronic obstructive lung disease (GOLD) guideline classifies
the severity of COPD into five stages, from stage 0 (being ‘at
risk’ for COPD, i.e. chronic bronchitis symptoms with no
apparent expiratory flow limitation) to stage IV (very severe
COPD, i.e. severe airflow limitation with or without chronic
respiratory failure).1
Expiratory flow response after administration of a
bronchodilator is widely and frequently used as an indicator
for the degree of reversibility of airflow limitation in
patients with COPD.2–4 In severe COPD, flow response after
bronchodilator may almost be negligible. Bronchodilator
response in terms of lung volumes has been addressed by
several authors, as well as the relationship between flow
response and volume response.5,6 A study in patients with
severe COPD showed a significant correlation between flow
and volume responses,7 and in a mixed group of patients
with mild to moderate COPD or asthma there were
significant bronchodilator responses in flow as well as in
volume indices.4
Expiratory flow limitation promotes dynamic hyperinfla-
tion and increased work of breathing in patients with severe
COPD.8 Bronchodilator-induced lung deflation has been
shown to increase ventilatory capacity and decrease
respiratory discomfort, thereby increasing exercise endur-
ance in patients with severe COPD.9–12 Patients with
moderate to severe COPD generally show a poor response
to bronchodilator in terms of flow, but the response in terms
of volume (including vital capacity) can be relatively good,
which is probably a reflection of reduced hyperinflation.7
Thus, it is likely that an increase of the expiratory volume
after inhalation of a bronchodilator reflects reduced lung
hyperinflation, i.e. a decrease of functional residual
capacity (FRC) or end-expiratory lung volume.4
So far, studies that have reported on the relationship
between expiratory flow and volume responses after
administration of a bronchodilator in COPD have been
rather small in terms of population size, were restricted to
patients with severe disease only, or included patients with
asthma as well. Therefore, the objective of our study was to
explore differences between flow and volume responses
after bronchodilator reversibility testing in patients over the
full range of clinical COPD stages (GOLD stage I to GOLD
stage IV). We hypothesized that the association between
flow and volume responses would reverse along with the
progression of the disease—i.e., that a large flow response
would be accompanied by a small volume response in
patients with mild COPD, and vice versa in patients with
severe COPD. The physiological mechanism underlying this
hypothesis comes from the previously reported observationof an altered and abnormal effect of lung inflation on
peripheral airway calibre in COPD patients with a significant
emphysematous component,13 which becomes more pre-
valent as the COPD becomes more severe.14 Because of
previous reports on varying bronchodilator response with
gender and smoking,15 we also explored associations
between these factors and flow and volume responses in
the consecutive GOLD stages.Methods
Study sample and selection of subjects
We used all available data from the ‘‘Stichting Huisartsen
Laboratorium Etten-Leur’’ (SHL), a regional diagnostic
centre that has been providing a range of diagnostic and
health care services (including spirometry) for over 330
general practitioners (GPs) in the South-Western part of the
Netherlands since 1997. Patients are referred to the SHL for
spirometry by their GP because they present with respira-
tory symptoms or other medical problems for which the GP
considers spirometry to be indicated. The SHL performs
approximately 5000 spirometric tests each year. About half
of all spirometry tests are from patients whose lung function
is assessed for diagnostic purposes, the remaining tests are
done as part of regular monitoring visits in patients who
have previously been diagnosed with COPD or asthma.
Spirometry test results and accompanying medical history
information are routinely assessed by a respiratory con-
sultant, and the referring GP receives the consultants’
report regarding the diagnosis, disease progression and/or
treatment recommendations.
In order to select patients with COPD from the database
(n ¼ 41,903 tests), we used the GOLD guideline criteria1 as
guidance. Figure 1 shows the details of the selection
procedure. We first omitted all records predating August
2001 because before that time smoking history, symptoms,
exacerbation history, medication use etcetera were not
uniformly recorded in the SHL spirometry database (step 1,
n ¼ 33,469 tests). In the next two selection steps, we
excluded patients o40 years of age (step 2, n ¼ 24,120
tests) and selected from the remaining tests those with a
post-bronchodilator FEV1/FVC ratioo0.70 (step 3, n ¼ 9246
tests). Because a substantial number of patients contributed
two or more tests to the database as they had been
monitored over the course of several years, we selected the
most recent test for each individual patient (step 4,
n ¼ 2684 tests). Next, we excluded all patients who
reported to be lifelong non-smokers, as well as patients
for whom either predicted lung function values could not be
calculated because body height was missing in the spiro-
metry database or information on current smoking status
was lacking (step 5, n ¼ 2288 tests). In order to subdivide
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Figure 1 Selection of patients from the SHL spirometry database, * as from August 2001, a standard format for recording medical
history information was implemented at the SHL, yfollowing the GOLD guideline criteria,1 z19 patients could not be classified because
information on body height was not present in the spirometry database; for 80 patients no information on smoking status had been
recorded, $at this stage, 12% of all patients were lifelong non-smokers, &DFVC and DFEV1 were extremely large in some patients
(most probably due to equipment malfunction), which had a significant impact on the results. Therefore, we chose to exclude
patients with DFVC and/or DFEV1 below the 1st percentile or above the 99th percentile.
Salbutamol flow and volume response in COPD 1357patients according to the severity of obstruction, we
calculated FEV1% predicted values
16 and classified patients
into one of the four GOLD stages: mild (stage I: FEV1 X80%
of predicted); moderate (stage II: FEV1 50–80% of pre-
dicted); severe (stage III: FEV1 30–50% of predicted); and
very severe COPD (stage IV: FEV1o30% of predicted).1 As no
information regarding the presence of chronic respiratory
failure was known, the criterion FEV1 o50% of predicted
plus chronic respiratory failure to classify a patient in GOLD
stage IV could not be applied.Measurements and outcomes
Spirometry (including formal bronchodilator reversibility
testing) was performed at 21 locations by five certified lung
function technicians. These technicians perform a minimum
of 100 spirometry tests per year and are regularly supervised
in central meetings. The technicians always work on thesame location and always use one and the same spirometer.
PC-based digital volume sensor spirometers (SpiroPerfects,
WelchAllyn, Delft, The Netherlands) were used on all
locations. This spirometer satisfies the American Thoracic
Society (ATS) standards.17 Following a local standard
operating procedure the spirometers were calibrated on a
daily basis with a 1-l syringe; within-test volume deviations
p3% were considered acceptable. Patient instruction,
assessment of acceptability of forced manoeuvres, and
criteria for test reproducibility were based on ATS recom-
mendations.17 Spirometry was performed at least 12 h after
the last inhalation of a short-acting bronchodilator or a long-
acting b-2 agonist, and at least 72 h after inhalation of
tiotropium.
Pre- and postbronchodilator measurements were per-
formed with subjects seated at rest before and 15min after
administration of four doses of 100 mg aerosolized salbuta-
mol by Volumatics spacer. After having inhaled one dose of
salbutamol the patient had to take 5–10 breaths before the
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ambient pressure were measured and entered into the
software to correct for BTPS (Body Temperature Pressure
Saturation).17 Reference equations for the calculation of
predicted values were those produced by the European
community for coal and steel (ECCS).16
Analysis
The Statistical Package for Social Sciences (SPSS version
12.0.1 for Windows, Chicago, IL, US) was used for the
analyses. Flow response (DFEV1) and volume response
(DFVC) were calculated by subtracting prebronchodilator
values from the corresponding salbutamol-induced post-
bronchodilator values and expressed in litres. Because of a
small number of extreme outliers with regard to flow as well
as volume responses—most probably due to by equipment
malfunction—which had a significant impact on the results,
we excluded patients with DFVC and/or DFEV1 below the
first percentile or above the 99th percentile (step 6 in Fig. 1,
n ¼ 2210 tests) from further analysis. Differences in subject
characteristics between GOLD stage subgroups were ana-
lysed by w2 testing and analysis of variance (ANOVA).
Differences in flow and volume responses between GOLD
stages and interaction between flow response, volume
response, and GOLD stage were statistically tested using a
multivariable linear regression model with DFVC as the
dependent variable and the first order interaction term of
GOLD stage and DFEV1 (i.e., DFVC ¼ intercept+GOLD
stage+DFEV1+[GOLD stageDFEV1]). This model was ex-
tended with gender, smoking status, and packyears as
covariates to adjust for their possible confounding effects
on the association between DFEV1 and DFVC. The R
2 statistic
was calculated to estimate the goodness-of-fit of the linear
regression model. Po0.05 was considered to be statistically
significant.Table 1 Characteristics of the study population.
GOLD I GOLD II G
n (%) 442 (20.0) 1297 (58.7) 4
Age (years) 60.9 (11.0) 62.5 (10.6) 6
Females (%) 37.6 36.8 3
Current smokers (%) 48.9 48.7 5
Packyears 27.9 (18.2) 32.7 (18.8) 3
Use of inhaled bronchodilators (%)
No 39.4 28.3 2
short-acting 16.3 16.4 1
long-actingy 44.3 55.3 6
post-BD FEV1 (l) 2.61 (0.58) 1.89 (0.49) 1
% predicted 89.0 (7.6) 65.6 (8.2) 4
post-BD FVC (l) 4.01 (0.90) 3.24 (0.85) 2
post-BD FEV1/FVC (%) 62.6 (4.6) 57.4 (7.5) 4
Values are means (standard deviation) unless stated otherwise.
Post-BD: post-bronchodilator; FEV1: forced expiratory volume in one
The remaining patients were former smokers; lifelong non-smoke
yWith or without concomitant use of a short-acting bronchodilatorResults
Subjects
After applying our selection criteria and exclusion of
extreme flow and volume response outliers, the final study
sample consisted of 2210 patients. All patients in the sample
reported one or more of the chronic respiratory symptoms
that are compatible with COPD (i.e., cough or sputum
production, with or without dyspnoea). Table 1 shows that
most patients (58.7%) were classified as moderate COPD
(GOLD stage II), whereas only 45 patients met the criteria
for very severe COPD (GOLD stage IV). The age range in the
sample was 40–91 years. Mean age increased from 60.9 (SD
11.0) years in GOLD stage I to 65.3 (SD 10.3) years in GOLD
stage III and IV. The overall proportions of women and
current smokers in the sample were 37% and 49%,
respectively, and these proportions did not differ between
the GOLD stages. The overall average smoking history was
32.4 (SD 18.6) packyears, with 27.9 (SD 18.2) packyears in
GOLD stage 1 up to 36.2 (SD 17.6) packyears in GOLD stage III
(Po0.001). The proportion of patients using a long-acting
bronchodilator increased from 44.3% in GOLD stage I to
73.3% in GOLD stage IV (Po0.001).
Flow and volume responses
Table 2 shows the responses on flow and volume indices after
salbutamol. The group mean values for DFEV1 and DFVC
were 0.180 l (SD 0.150) and 0.226 l (SD 0.227), respectively.
DFEV1 decreased as the GOLD stage became more severe
(Po0.001, multivariable linear regression model; full results
of the regression analysis not shown), whereas DFVC
changed in the opposite direction, i.e. increased from
0.169 (SD 0.191) in GOLD stage I to 0.306 (SD 0.254) in GOLD
stage IV (Po0.001). The R2 values of the linear regressionOLD III GOLD IV Total P
26 (19.3) 45 (2.0) 2210 (100.0)
5.3 (10.3) 65.1 (10.3) 62.8 (10.7) o0.001
8.3 31.1 37.1 0.793
0.9 40.0 49.0 0.544
6.2 (17.6) 34.4 (19.0) 32.4 (18.6) o0.001
3.5 15.6 29.5
5.8 11.1 16.1
0.7 73.3 54.4 o0.001
.16 (0.28) 0.71 (0.16) 1.87 (0.68) o0.001
2.1 (5.5) 24.6 (3.9) 64.9 (17.5) o0.001
.55 (0.78) 2.13 (0.70) 3.24 (0.97) o0.001
6.7 (9.7) 37.1 (8.9) 55.8 (9.6) o0.001
second. FVC: forced vital capacity.
rs were excluded from the sample.
.
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Table 2 Responses (D) after salbutamol testing by GOLD stage.
GOLD I (n ¼ 442) GOLD II (n ¼ 1297) GOLD III (n ¼ 426) GOLD IV (n ¼ 45) Total (n ¼ 2210) P
DFEV1 (l) 0.211 (0.167) 0.186 (0.151) 0.139 (0.115) 0.075 (0.115) 0.180 (0.150) o0.001
D% predicted 7.13 (5.52) 6.47 (5.15) 5.02 (4.01) 2.66 (2.58) 6.25 (5.06) o0.001
DFVC (l) 0.169 (0.191) 0.228 (0.225) 0.269 (0.250) 0.306 (0.254) 0.226 (0.227) o0.001
D% predicted 4.75 (5.46) 6.49 (6.43) 7.83 (7.23) 8.57 (6.93) 6.44 (6.50) o0.001
DFEV1/FVC (%) 2.6 (3.2) 1.8 (3.7) 0.7 (4.4) 2.1 (6.7) 1.7 (3.9) o0.001
Values are means (standard deviation).
FEV1: forced expiratory volume in 1 s. FVC: forced (expiratory) vital capacity.
Multivariable linear regression analysis, testing for difference between GOLD stages, with adjustment for gender, smoking status,
and packyears.
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Figure 2 Relationship between FVC and FEV1 responses in the
GOLD stages (Po0.001) Linear R2: GOLD I ¼ 0.401; GOLD
II ¼ 0.418; GOLD III ¼ 0.381; GOLD IV ¼ 0.151.
Salbutamol flow and volume response in COPD 1359models ranged from 0.151 for GOLD stage IV to 0.418 for
GOLD stage II.
The scatter plot in Fig. 2 shows the relationship between
DFEV1 and DFVC for the respective GOLD stages. The plot
clearly shows a positive correlation between DFEV1 and
DFVC within each stage (Po0.01), but also that the
relationship differed between the GOLD stages (Po0.001).
From GOLD stage I to GOLD stage III the slope of the
regression line became gradually steeper, which indicates
that a particular FEV1 response was accompanied by a higher
FVC response as the GOLD stage was more severe. The
exception was GOLD stage IV, in which the slope was similar
as the slope in GOLD stage III. The R2 values of the linearregression models ranged from 0.151 for GOLD stage IV to
0.418 for GOLD stage II.
While exploring differential effects of smoking status on
volume response between the GOLD stages, current smokers
in GOLD stages I and II appeared to have somewhat lower
DFVC values compared with former smokers, which was
opposite in GOLD stages III and IV (Fig. 3). However,
statistical testing did not show significant associations with
smoking status in combination with GOLD stage for either
DFVC (P ¼ 0.422) or DFEV1 (P ¼ 0.947). We did not observe
any statistically significant differential effects of packyears
or gender on DFVC nor DFEV1 between the GOLD stages.
Discussion
This study was a cross-sectional analysis of differences in,
and associations between salbutamol-induced flow and
volume responses during routine spirometry reversibility
testing in a large sample of general practice patients who
were classified according to the GOLD severity stages. We
tested the hypothesis that the association between flow and
volume responses changes as COPD becomes more severe.
The findings seem to support this hypothesis and connect
with previous reports in smaller samples of patients with
moderate to severe COPD.4,7,11 The GOLD stage ‘shift’ in the
association between flow and volume response may be
explained by the fact that FEV1 is determined by the airflow
at high to medium lung volumes, whereas FVC is mainly
determined by airway narrowing and flow limitation at low
lung volumes. Therefore, a postbronchodilator change in
FVC without a concomitant change of FEV1 suggests that the
airway smooth muscle tone—which is the point of impact of
all inhaled bronchodilators—is a major determinant of
airway calibre at low, but not at high lung volumes.13 The
altered effect of lung inflation on airway calibre, due either
to loss of lung elastic recoil or compression by enlarged
(emphysematous) air spaces may explain the lack of
sensitivity to bronchodilatation as assessed by changes in
FEV1 in the more severe stages of COPD.
Strengths and limitations of the study
A particular strength of this study is the size and width of
the patient population: to our knowledge no previous study
has reported on a patient sample this large that comprised
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Figure 3 Differences in FVC (A) and FEV1 (B) responses
according to GOLD and smoking status.
T. Schermer et al.1360the full range of clinical COPD stages, including mild COPD.
This is a clear advantage of using lung function data that
have been obtained for routine diagnostic purposes in
primary care. However, apart from being an advantage this
automatically is a disadvantage as well: the primary care
laboratory does not have access to the patients’ medical
record in the general practice, and even though all
spirometry and medical history data are assessed by a
respiratory consultant, no formal clinical diagnosis of COPD
could be established. We do have additional data regarding
respiratory symptoms, (self-reported) bronchial hyperre-
sponsiveness and allergies, and family history of respiratory
disease for all the patients in our final sample. However, as
none of these characteristics is specific for asthma we
decided not to use this information to exclude patients. It is
important to realize that COPD and asthma can co-exist
within the same patient18 and, consequently, that even
‘typical’ asthma characteristics like the presence of
bronchial hyperresponsiveness19 or a lack of bronchodilator
reversibility20 cannot always distinguish COPD from asthma.
Combined with the facts that patients without a smoking
history were excluded, that the average smoking history in
the sample was substantial, and that all patients in the final
dataset reported at least one chronic respiratory symptom
that is compatible with COPD, we believe that all patients in
our sample had indeed COPD, although some of them may
have had an asthma component along with it. Another
disadvantage of these routine care data is that neither more
advanced lung function tests (body plethysmography,
determination of diffusion capacity) nor radiological diag-
nostic procedures (chest X-rays, CT scans) are routinely used
in general practice to diagnose patients with COPD, and
were therefore not available in the database. This clearly
limited our possibilities to characterize the patients with
regard to the presence of an emphysematous component, or
to establish the actual presence of lung hyperinflation, or
salbutamol-induced changes in hyperinflation. Findings
reported by O’Brien and colleagues from a primary care
sample of patients with COPD indicate that significant
emphysema will most probably have been present in a
substantial proportion of our sample: 51% of a patient group
with mild to severe obstruction showed radiological evi-
dence of emphysema on high resolution CT scans.14 For the
Dutch population, the distribution of COPD severity over the
consecutive GOLD stages has recently been estimated by
classifying all patients from two different general practice
data sources.21 With 55% of all patients, moderate COPD was
the predominant stage, followed by mild (27%), severe (15%)
and very severe (3%) COPD.21 This distribution was very
similar to the severity distribution in our study sample,
which demonstrates its representiveness of the COPD
patient population in our country. The relatively small
number of GOLD stage IV patients in the sample is not
surprising, as this category of patients is generally treated
by secondary care chest physicians and cannot be expected
to be present more than occasionally in the typical primary
care patient population that we have studied.
Addition of an anticholinergic agent was not a part of the
bronchodilator reversibility testing protocol at the labora-
tory sites. The use of salbutamol alone will probably not
have achieved maximal bronchodilatation in all patients,
because the combination of a b-2 agonist with ipratropium
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of a b-2 agonist alone in terms of bronchodilatation in
COPD.22,23 We cannot be sure whether or not this has
affected the observed association between flow and volume
response in the respective GOLD stage subgroups, as we
have not been able to trace any evidence showing that
disease severity is a determinant of differential bronchodi-
lator response to a short-acting b-2 agonist or ipratropium
bromide.Implications for clinical practice
A practical implication of our and previous findings is that it
is important to realise that patients with COPD—even if
nonresponders in terms of FEV1—may benefit from broncho-
dilators because they can breathe at a lower lung volume
due to reduced airtrapping, notwithstanding the fact that
they are still flow limited.7 This may have direct con-
sequences for the level of dyspnoea that patients perceive,
especially during physical activity.9–12 A better ‘mapping’ of
volume response next to flow response during bronchodi-
lator reversibility testing can improve the physicians’
understanding of reduced dyspnoea in the absence of an
effect on flow limitation (obstruction) in individual COPD
patients. Although more advanced pulmonary function tests
are useful in assessing and monitoring parenchymal damage
and the presence of hyperinflation,24 this is not feasible for
all patients with COPD treated in primary care. However,
the kind of equipment used in most primary care labora-
tories would enable measurement of inspiratory capacity
(IC) as a part of the spirometry routine. Because an increase
in IC reflects a reduction of hyperinflation,11 an impression
of the presence of hyperinflation could be obtained without
the actual determination of RV/TLC or FRC being necessary.
Whether a more profound insight in the degree of
bronchodilator volume response or the presence of hyperin-
flation actually adds to the management of patients with
COPD—including the choice of therapeutic options like the
type of bronchodilator medication and physical exerci-
se—and, ultimately, to patients’ health needs to be
established.
In conclusion, this study in a primary care COPD
population confirms our hypothesis that patients on the
milder side of the GOLD severity spectrum differ from the
more severe patients with regard to their response on a
bronchodilator in terms of flow (FEV1) and volume (FVC).
This difference is probably explained by the higher degree of
loss of lung elastic recoil and/or compression of the smaller
airways by enlarged air spaces that accompanies the
progression of COPD to the more severe stages.Acknowledgements
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